Sight Sciences (SGHT)

• Market cap: $180M
• 1 day: 6.25%
• 5 days: 0.28%
• 1 month: -4.29%
• 3 months: -46.72%
• 6 months: -43.87%
• Year to date: -30.00%
• 1 year: 7.21%
• 5 years: -89.34%
• 10 years: -89.34%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Employees: 214

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

471% more call options, than puts

Call options by funds: $468K | Put options by funds: $82K

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

88% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 16

11% more funds holding

Funds holding: 70 [Q2] → 78 (+8) [Q3]

0.06% less ownership

Funds ownership: 34.15% [Q2] → 34.09% (-0.06%) [Q3]

5% less capital invested

Capital invested by funds: $113M [Q2] → $108M (-$5.36M) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4.60 29% upside
• Avg. target: $5.15 44% upside
• High target: $5.50 54% upside

4 analyst ratings

• positive: 1 25%
• neutral: 3 75%
• negative: 0 0%

Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target	29% upside $4.60	Neutral Maintained	11 Dec 2024
UBS Danielle Antalffy 38% 1-year accuracy 5 / 13 met price target	54% upside $5.50	Buy Initiated	6 Dec 2024
Morgan Stanley Cecilia Furlong 20% 1-year accuracy 1 / 5 met price target	40% upside $5	Equal-Weight Maintained	11 Nov 2024
Piper Sandler Matt O'Brien 58% 1-year accuracy 30 / 52 met price target	54% upside $5.50	Neutral Reiterated	8 Nov 2024